BRCA1 and non-small cell lung carcinoma: Our retrospective evaluation of 54 NSCLC patients who had received platinum-based chemotherapy revealed 20 carrying HR gene mutations, eight carrying BRCA1/2 mutations, and 22 carrying driver gene mutations (Table 2).